Arkolith/Insider Trading/FUSN/Form 4

Leamon Christopher P

Chief Scientific OfficerFusion Pharmaceuticals Inc. (FUSN) · full profile →Form 4 · filed Jan 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 31, 2023Grant(A)12K——12K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 4, 2024Grant(A)64K—$064K
Jan 4, 2024Grant(A)106K—$0106K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-002301) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML